Brief: Pardes Biosciences Inc Says Pomotrelvir Did Not Meet Primary Endpoint

Pardes Biosciences

03/04/2023 14:54

April 3 (Reuters) - Pardes Biosciences Inc  PRDS.O :
    * PARDES BIOSCIENCES INC - POMOTRELVIR WAS WELL TOLERATED, WITH
TREATMENT-EMERGENT, DRUG-RELATED NAUSEA IN 3.1% OF PARTICIPANTS 
    * PARDES BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM PHASE 2 TRIAL
EVALUATING
POMOTRELVIR FOR THE TREATMENT OF COVID-19
    * PARDES BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM PHASE 2 TRIAL
EVALUATING
POMOTRELVIR FOR THE TREATMENT OF COVID-19
    * PARDES BIOSCIENCES INC - POMOTRELVIR DID NOT MEET PRIMARY ENDPOINT
    * PARDES BIOSCIENCES INC - TO SUSPEND FURTHER CLINICAL DEVELOPMENT OF
POMOTRELVIR
AND EXPLOREA RANGE OF STRATEGIC ALTERNATIVES
    * PARDES BIOSCIENCES INC - AS OF MARCH 31, 2023, CO'S PRELIMINARY CASH, CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED ABOUT $172.4 MILLION
    * PARDES BIOSCIENCES INC - BOARD OF DIRECTORS HAS INITIATED A REVIEW OF A
RANGE OF
STRATEGIC ALTERNATIVES


Further company coverage:  PRDS.O 

 ((Reuters.Briefs@thomsonreuters.com;))